Abbott Laboratories $1.3 Billion Notes Offering

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650 million aggregate principal amount of 1.400% notes due 2030. The net proceeds from the offering will be used for general corporate purposes, which may include, without limitation, the repayment of indebtedness.

Abbott is a global healthcare company that researches and manufactures a range of medical technologies. With a portfolio of leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Abbott serves people in more than 160 countries and employs approximately 107,000 people.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick, counsel Jeffrey S. Ramsay and associate Ariel Rivera. Counsel Loyti Cheng and associate Michael Comstock provided environmental advice. Counsel Ethan R. Goldman and associate Sunny Kim provided tax advice. Partner Frank J. Azzopardi and associate Jay Frankel provided intellectual property advice. All members of the Davis Polk team are based in the New York office.